ArticleBiomaterials research2025
A New Light-Sensor System Affecting Cancer Cell Fate.
Article in Biomaterials research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A new physiological photopolymerizing system with relevant effects on proteins and able to affect cancer cell fate was discovered here. The riboflavin-phosphocholine-light (RPL) system induces lysozyme (LYZ) photopolymerization in vitro, affecting the cell viability of cancer cells, in both 2-dimensional and 3-dimensional cell cultures. The RPL treatment of nontumoral, mesenchymal stem cells, or cancer cells shows a distinct behavior, depending on the ectopic presence of LYZ. Morphological changes and cellular aggregation of the cancer cells were induced by the treatment. The presence of both phosphocholine and high levels of LYZ expression at the breast cancer cell-cell interface seems to create a vulnerability for this new photodynamic system under visible light exposure. Further, we generated 2 new riboflavin-phosphocholine hydrogels (RPHy and RPHy-LYZ) by light-emitting diode exposure. A transdifferentiation into osteoblast-like cells of a triple-negative breast cancer cell line, embedded into RPHy, was detected, while cell death was observed using RPHy-LYZ
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.